Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Biomea Fusion

Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study

Biomea Fusion Inc‘s (NASDAQ:BMEA) stock price plummeted after the company priced its public offering.

Is This Growth Stock Under $10 With 370% Upside a Buy Right Now?

Is This Growth Stock Under $10 With 370% Upside a Buy Right Now?

This biotech company has some promising candidates in its pipeline. Could this minor setback slow the company's progress?

Wall Street Expects 190% Upside for This Biotech Stock

Wall Street Expects 190% Upside for This Biotech Stock

It's not just AI stocks that have piqued Wall Street’s attention - analysts also think this biotech stock is set for massive growth, with forecasts calling for the share price to nearly triple over the next 12 months.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Markets Today: Stocks Mixed Ahead of U.S. CPI Report Tuesday and FOMC Meeting

Morning Markets The S&P 500 Index ( $SPX ) ( SPY ) is up +0.11%, the Dow Jones Industrials Index ( $DOWI ) ( DIA ) is up +0.3%, and the Nasdaq 100 Index ( $IUXX ) ( QQQ ) is down -0.26%. Stock index futures this morning are mixed...

Markets Today: Stocks Slightly Lower Ahead of U.S. CPI Report Tuesday and FOMC Meeting

Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are down -0.10%, and Dec Nasdaq 100 E-Mini futures (NQZ2 3) are down -0.18%. Stock index futures this morning are modestly lower on position squaring ahead of Tuesday’s U.S. consumer price report and the results of the Tue/Wed FOMC meeting. U.S....

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

Biomea Fusion Commences Initial-Stage Study For Plasma Cell Cancer Setting

Biomea Fusion (NASDAQ: BMEA) has dosed the the first patient in the multiple myeloma (MM) cohort of the Phase I clinical trial evaluating BMF-219, a covalent menin inhibitor. Multiple myeloma (MM) is a cancer of plasma cells, which make antibodies (immunoglobulins) and are mainly located in the bone marrow.

inkl

Read news from The Economist, FT, and more,
with one subscription

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

1

Organisations

US Federal Reserve

Bank of England

European Medicines Agency

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

377,670 stories

139,830 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play